Drugs / Theravex
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07627633 | Oct 2026 → Oct 2028 expected | — | Ain Shams University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Theravex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07627633 ↗ |
| Known as | BBL | “Bone Bioactive Liquid (BBL, Theravex Tissue Care Plus) is a novel, negatively charged phosphate saline solution containing calcium and magnesium chlorides that fundamentally...” NCT07627633 ↗ |
| Known as | Bone Bioactive Liquid | “The purpose of this clinical study is to evaluate the clinical and radiographic efficacy of Theravex Tissue Care Plus (Bone Bioactive Liquid) as an adjunct to a xenograft in...” NCT07627633 ↗ |
| Known as | Theravex Tissue Care Plus | “The purpose of this clinical study is to evaluate the clinical and radiographic efficacy of Theravex Tissue Care Plus (Bone Bioactive Liquid) as an adjunct to a xenograft in...” NCT07627633 ↗ |